Woman who died after receiving AstraZeneca vaccine had ‘unusual symptoms’: report


A 60-year-old Danish woman who received the AstraZeneca COVID-19 vaccine had “very unusual symptoms” before dying from a blood clot, according to a report.

The woman had a low number of platelets and clots in small and large vessels, Reuters reported, citing the Danish Medicines Agency.

The agency cited some similar cases reported in Norway and in the European Medicines Agency’s database on drug side effects, according to the news outlet.

“It was an unusual course of illness around death that caused the Danish Medicines Agency to react,” he said in a statement Sunday night.

On Saturday, Norway said three people, all under the age of 50, who had received the injection were being treated in a hospital for bleeding, blood clots and a low blood platelet count, which health officials labeled “” unusual symptoms. “

Denmark, Norway and Iceland said last week that they would stop introducing the AstraZeneca injection.

Norway said that three people who had received the AstraZeneca injection were being treated in a hospital for bleeding and blood clots.
REMKO DE WAAL / ANP / AFP via Getty Images

European vaccination programs have been shaken by recent reports that recipients of AstraZeneca inoculation have suffered from blood clots.

AstraZeneca tried to quell safety concerns after blood clots appeared in some people who received the COVID-19 vaccine.
AstraZeneca tried to quell safety concerns after blood clots appeared in some people who received the COVID-19 vaccine.
Chris Jackson / Getty Images

The European Medicines Agency has said there is no indication the cases were related to vaccination, a view echoed by the World Health Organization on Friday.

AstraZeneca tried to quell safety concerns after blood clots appeared in some people, prompting a dozen countries to stop using some or all of their doses.

The British pharmacist’s review of the safety data of more than 17 million people who received the injection in the UK and the European Union found no evidence of an increased risk of pulmonary embolism or deep vein thrombosis, conditions associated with clots. it said in a statement Sunday. .

There were also no signs of an increased risk of thrombocytopenia, a low blood platelet count, according to AstraZeneca.

.

Source link